Lyophilized mRNA-lipid nanoparticle vaccine - Wuhan Recogen Biotechnology
Alternative Names: Lyo-mRNA-Delta; Lyo-mRNA-Omicron; Lyo-mRNA-WT; mRNA-LNP nanoparticle vaccine; mRNA-LNP vaccine; R-520ALatest Information Update: 28 Jun 2022
At a glance
- Originator Wuhan Rhecogen Biotechnology
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 27 Jun 2022 Jiangsu Recbio Technology receives clinical trial approval from the Food and Drug Administration of the Philippines for lyophylised mRNA lipid nanoparticle vaccine in COVID-2019 infections
- 27 Jun 2022 Jiangsu Recbio Technology plans a clinical trial for COVID-2019 infections in Philippines
- 14 Feb 2022 Preclinical trials in COVID-2019 infections (Prevention) in China (IM)